Compare Diamondback Energy Inc (FANG) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Cassava Sciences Inc — how do they compare? Diamondback Energy Inc trades at $200.95 (market cap $56.48B), while Cassava Sciences Inc trades at $0.95 (market cap $47.75M). The key difference: Diamondback Energy Inc is far larger — about 1182.8× Cassava Sciences Inc's market cap, and Diamondback Energy Inc pays a 2.18% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FANG | FLNA | |
|---|---|---|
Market Cap | $56.48B | $47.75M |
Sector | Energy | Health |
52-Week High | $213.69 | $4.64 |
52-Week Low | $134.53 | $0.87 |
Enterprise Value | $68.63B | -$34.93M |
Dividend Yield | 2.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $200.97, up 1.01% with strong bullish technical signals and positive earnings momentum. The company delivered Q2 2026 EPS of $6.48, beating estimates by 6.6%, while revenue growth accelerated to $14.93B in 2025. Analyst consensus remains overwhelmingly bullish with 90% buy ratings and a $236.63 price target, representing 18% upside potential. Recent news highlights operational excellence and production growth guidance increases.
The outlook remains positive with production growth and debt reduction supporting valuation expansion. Key risks include oil price volatility and execution challenges amid global supply disruptions. Institutional interest remains strong with recent positions from Balefire LLC, though some trimming occurred from Bank of Nova Scotia. The combination of earnings beats, improved guidance, and favorable technicals suggests continued upward momentum.
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
